have led investments in more than 50 companies
and have an established track record of working closely with management teams
in early and growth stage enterprises. These private and public companies have
achieved substantial clinical and commercial success in their industry segments
and have generated superior investment returns. In addition, the partners have
significant biomedical and life science industry operating experience, and extensive
research training from premier institutions including Harvard Medical School and UCSF Medical School.
Notable investments include Aveo Pharmaceuticals (NASDAQ: AVEO), Complete Genomics (NASDAQ: GNOM), Gloucester Pharmaceuticals (NASDAQ: CELG acquired), Healtheon (NASDAQ: WBMD merged), Idun Pharmaceuticals (NYSE: PFE acquired), Intuitive Surgical (NASDAQ: ISRG), Millennium Pharmaceuticals (Takeda Pharmaceutical acquired), Novacept (NASDAQ: HOLX acquired), Opus Medical (NASDAQ: ARTC acquired), Rinat Neuroscience (NYSE: PFE acquired), Senomyx (NASDAQ: SNMX), SurgRx (NYSE: JNJ acquired), Tercica (NYSE: IPN acquired), and Visiogen (NYSE: ABT acquired).